Trial · NCT00257322
Cellular Immune Augmentation in Colon and Rectal Cancer
NCT00257322, Phase 2, Completed, University of California, Irvine; results first posted 2016-04-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cellular Immune Augmentation in Colon and Rectal Cancer. Trials, record NCT00257322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00257322
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cellular Immune Augmentation in Colon and Rectal Cancer
- NCT number
- NCT00257322
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of California, Irvine
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- GM-CSF
- First posted
- 2005-11-22
- Last updated
- 2018-10-31
- Results first posted
- 2016-04-26
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participants Exhibiting Immune Response | 24 Months | Immunological dendritic cell and cellular immune responses to GM-CSF administered in conjunction with chemotherapy for patients with advanced colorectal cancer. |
| Secondary | Response Rates and Overall Survival. | 24 Months | Effect of cellular immune stimulation on response rates and overall survival. This is a secondary endpoint and while data will be recorded, a larger study with improved power will be necessary to confirm any improvements noted. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Response Rates and Overall Survival. | 24 Months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Participants Exhibiting Immune Response | 24 Months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rates and Overall Survival. | Chemo Therapy and GM-CSF | Response Rates | 16 | Participants | |
| Response Rates and Overall Survival. | Chemo Therapy and GM-CSF | Overall Survival | 16 | Participants | |
| Participants Exhibiting Immune Response | Chemo Therapy and GM-CSF | 11 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chemo Therapy and GM-CSF | 20 | |
| Overall Study | COMPLETED | Chemo Therapy and GM-CSF | 16 | |
| Overall Study | NOT COMPLETED | Chemo Therapy and GM-CSF | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chemo Therapy and GM-CSF | ||
| Total, other adverse events | Chemo Therapy and GM-CSF | 0 | 20 |
| Total, serious adverse events | Chemo Therapy and GM-CSF | 0 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22270330 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00257322
GET https://conductscience.org/api/trials/v1/NCT00257322/registered